Cargando…
Medical Therapy with Pasireotide in Recurrent Cushing’s Disease: Experience of Patients Treated for At Least 1 Year at a Single Center
Subcutaneous (SC) injection of pasireotide, a somatostatin analog, is approved for the treatment of adults with Cushing’s disease (CD) for whom pituitary surgery was unsuccessful or is not an option. We highlight the symptomatic and biochemical improvement of six patients with recurrent CD treated w...
Autores principales: | Yedinak, Chris G., Hopkins, Sarah, Williams, Jessica, Ibrahim, Aly, Cetas, Justin Schultz, Fleseriu, Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327352/ https://www.ncbi.nlm.nih.gov/pubmed/28289402 http://dx.doi.org/10.3389/fendo.2017.00035 |
Ejemplares similares
-
Monitoring Patient Improvement Parameters following Pasireotide Treatment in Cushing's Disease
por: Yedinak, Chris, et al.
Publicado: (2013) -
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023) -
Hypercoagulability in Cushing Syndrome, Prevalence of Thrombotic Events: A Large, Single-Center, Retrospective Study
por: Suarez, Maria Gabriela, et al.
Publicado: (2019) -
Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study
por: Fleseriu, Maria, et al.
Publicado: (2019) -
Hypercortisolemia Recurrence in Cushing's Disease; a Diagnostic Challenge
por: Hinojosa-Amaya, José Miguel, et al.
Publicado: (2019)